Race Oncology Ltd (RAC:ASX)
Race Oncology Limited (Race) is an Australia-based precision oncology company with a Phase 2/3 cancer drug, Bisantrene. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The Company is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.